Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nexiguran zeltasiguran
- Development stage
- Preclinical
- Lead developer
- Intellia Therapeutics
- Modality
- Gene Editing → Gene Therapies
- Administration
- Intravenous
01
Overview
Nexiguran zeltasiguran is an investigative gene editing therapy being developed through a global collaboration between Regeneron and Intellia Therapeutics. It is designed as a TTR-targeting candidate for the treatment of transthyretin amyloidosis (ATTR).
02
Targets
TTR (Transthyretin)
Beyond the preview
Go deeper on nexiguran zeltasiguran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nexiguran zeltasiguran.